Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Sanofi said the results are strong enough to support a new indication in the US and EU for Libtayo, a PD-1 inhibitor that is already FDA-approved in advanced cutaneous squamous cell carcinoma.

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

The primary measure of success, disease-free survival (DFS), showed significant improvement with Libtayo treatment. The median follow-up period was ... on investigational use, and its safety ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

The primary measure of success, disease-free survival (DFS), showed significant improvement with Libtayo treatment. The median follow-up period was 24 months ... treatment is based on investigational ...